{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T20:57:48Z","timestamp":1792270668870,"version":"4.4.0"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2009,9,30]],"date-time":"2009-09-30T00:00:00Z","timestamp":1254268800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0007258","type":"journal-article","created":{"date-parts":[[2009,9,29]],"date-time":"2009-09-29T21:49:05Z","timestamp":1254260945000},"page":"e7258","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":380,"title":["Masitinib (AB1010), a Potent and Selective Tyrosine Kinase Inhibitor Targeting KIT"],"prefix":"10.1371","volume":"4","author":[{"given":"Patrice","family":"Dubreuil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00e9bastien","family":"Letard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ciufolini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Gros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Humbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Cast\u00e9ran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurence","family":"Borge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9reng\u00e8re","family":"Hajem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Lermet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Sippl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwige","family":"Voisset","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Arock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Auclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phillip S.","family":"Leventhal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colin D.","family":"Mansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alain","family":"Moussy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2009,9,30]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bbrc.2005.08.055","article-title":"Signaling by Kit protein-tyrosine kinase - the stem cell factor receptor.","volume":"337","author":"R Roskoski Jr","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1182\/blood.V90.4.1345","article-title":"Stem cell factor and hematopoiesis.","volume":"90","author":"VC Broudy","year":"1997","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.ejphar.2005.12.067","article-title":"Stem cell factor and its receptor c-Kit as targets for inflammatory diseases.","volume":"533","author":"L Reber","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1358\/dof.2008.033.02.1164207","article-title":"Kit mutations in cancer and their treatment with protein kinase inhibitors.","volume":"33","author":"U Tests","year":"2008","journal-title":"Drugs Fut"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1634\/stemcells.2004-0117","article-title":"Normal and Oncogenic Forms of the Receptor Tyrosine Kinase Kit.","volume":"23","author":"J Lennarttson","year":"2005","journal-title":"Stem Cells"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1111\/j.1365-2141.2007.06619.x","article-title":"Recent advances in the understanding of mastocytosis: the role of KIT mutations.","volume":"138","author":"A Orfao","year":"2007","journal-title":"Br J Haematol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1124\/jpet.105.084145","article-title":"Role of tyrosine kinase inhibitors in cancer therapy.","volume":"315","author":"A Arora","year":"2005","journal-title":"J Pharmacol Exp Ther"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"2558","DOI":"10.1073\/pnas.92.7.2558","article-title":"Selective inhibition of the platelet-derived growth factor signal transduction pathway by a protein-tyrosine kinase inhibitor of the 2-phenylaminopyrimidine class.","volume":"92","author":"E Buchdunger","year":"1995","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref9","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative.","volume":"56","author":"E Buchdunger","year":"1996","journal-title":"Cancer Res"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3127","DOI":"10.1182\/blood-2004-10-3967","article-title":"Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib.","volume":"105","author":"AL Dewar","year":"2005","journal-title":"Blood"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"55827","DOI":"10.1074\/jbc.M409792200","article-title":"A novel mode of Gleevec binding is revealed by the structure of spleen tyrosine kinase.","volume":"279","author":"S Atwell","year":"2004","journal-title":"J Biol Chem"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1038\/labinvest.3700466","article-title":"Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumours.","volume":"86","author":"BP Rubin","year":"2006","journal-title":"Lab Invest"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations.","volume":"99","author":"Y Ma","year":"2002","journal-title":"Blood"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF02982808","article-title":"Constitutive activation of c-kit by the juxtamembrane but not the catalytic domain mutations is inhibited selectively by tyrosine kinase inhibitors STI571 and AG1296.","volume":"76","author":"S Ueda","year":"2002","journal-title":"Int J Hematol"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1038\/nm1446","article-title":"Cardiotoxicity of the cancer therapeutic agent imatinib mesylate.","volume":"12","author":"R Kerkela","year":"2006","journal-title":"Nat Med"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"4044","DOI":"10.1172\/JCI32373","article-title":"An anticancer C-Kit kinase inhibitor is reengineered to make it more active and less cardiotoxic.","volume":"117","author":"A Fernandez","year":"2007","journal-title":"J Clin Invest"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1182\/blood.V85.3.790.bloodjournal853790","article-title":"Constitutively activating mutations of c-kit receptor tyrosine kinase confer factor-independent growth and tumourigenicity of factor-dependent hematopoietic cell lines.","volume":"85","author":"H Kitayama","year":"1995","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1182\/blood.V79.4.958.bloodjournal794958","article-title":"The c-kit receptor ligand functions as a mast cell chemoattractant.","volume":"79","author":"CJ Meininger","year":"1992","journal-title":"Blood"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"4710","DOI":"10.1038\/sj.onc.1206587","article-title":"Signal transduction by several KIT juxtamembrane domain mutations.","volume":"22","author":"N Casteran","year":"2003","journal-title":"Oncogene"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood.V87.1.273.273","article-title":"Constitutive activation of c-kit in FMA3 murine mastocytoma cells caused by deletion of seven amino acids at the juxtamembrane domain.","volume":"87","author":"T Tsujimura","year":"1996","journal-title":"Blood"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1182\/asheducation-2006.1.178","article-title":"FLT3 mutations: biology and treatment.","author":"D Small","year":"2006","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref22","first-page":"4236","article-title":"Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).","volume":"62","author":"B Nagar","year":"2002","journal-title":"Cancer Res"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"31655","DOI":"10.1074\/jbc.M403319200","article-title":"Structural basis for the autoinhibition and STI-571 inhibition of c-Kit tyrosine kinase.","volume":"279","author":"CD Mol","year":"2004","journal-title":"J Biol Chem"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"7099","DOI":"10.1158\/0008-5472.CAN-04-1443","article-title":"BAY 43-9006 exhibits broad spectrum oral antitumour activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumour progression and angiogenesis.","volume":"64","author":"SM Wilhelm","year":"2004","journal-title":"Cancer Res"},{"key":"ref25","first-page":"327","article-title":"In vivo antitumour activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic\/pharmacodynamic relationship.","volume":"9","author":"DB Mendel","year":"2003","journal-title":"Clin Cancer Res"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"137","DOI":"10.14712\/fb2006052040137","article-title":"Protein kinase inhibitors.","volume":"52","author":"I Shchemelinin","year":"2006","journal-title":"Folia Biol (Praha)"},{"key":"ref27","year":"2001"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.onc.1206120","article-title":"Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms.","volume":"22","author":"Y Zermati","year":"2003","journal-title":"Oncogene"},{"key":"ref29","first-page":"1115","article-title":"Juxtamembrane mutant V560GKit is more sensitive to Imatinib (STI571) compared with wild-type c-kit whereas the kinase domain mutant D816VKit is resistant.","volume":"1","author":"MJ Frost","year":"2002","journal-title":"Mol Cancer Ther"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.","volume":"348","author":"J Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1939-1676.2008.0190.x","article-title":"Masitinib is Safe and Effective for the Treatment of Canine Mast Cell Tumors.","volume":"22","author":"KA Hahn","year":"2008","journal-title":"J Vet Intern Med"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1182\/blood-2005-06-2433","article-title":"Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells.","volume":"108","author":"M Gabillot-Carre","year":"2006","journal-title":"Blood"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1067\/mai.2001.115753","article-title":"Autocrine regulation of cord blood-derived human mast cell activation by IL-10.","volume":"108","author":"B Royer","year":"2001","journal-title":"J Allergy Clin Immunol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1084\/jem.157.1.189","article-title":"IgE mediated release of leukotriene C4, chondroitin sulfate E proteoglycan, beta-hexosaminidase, and histamine from cultured bone marrow-derived mouse mast cells.","volume":"157","author":"E Razin","year":"1983","journal-title":"J Exp Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/31269","article-title":"Function of the chemokine receptor CXCR4 in haematopoiesis and in cerebellar development.","volume":"393","author":"YR Zou","year":"1998","journal-title":"Nature"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1021\/jm0203783","article-title":"Comparative evaluation of 11 scoring functions for molecular docking.","volume":"46","author":"R Wang","year":"2003","journal-title":"J Med Chem"},{"key":"ref37"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0007258","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,12]],"date-time":"2025-02-12T12:23:28Z","timestamp":1739363008000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0007258"}},"subtitle":[],"editor":[{"given":"Joseph Alan","family":"Bauer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2009,9,30]]},"references-count":37,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2009,9,30]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0007258","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,9,30]]}}}